Technavio, a tech-focused market research firm, has published a new report on the global rabies treatment market, which is expected to grow at a CAGR of close to 5% during the forecast period 2017-2021.
Based on geographical segmentation, Technavio market researchers categorize the global rabies treatment market into the following key regions: the Americas, APAC, and EMEA.
Source: Technavio
Click here to request a free sample of this report
Top three contributors for the global rabies treatment market are elaborated below:
Rabies treatment market in the Americas: Fueled by the increasing incidence of and mortality rate associated with human rabies, coupled with rising awareness about vaccinations of dogs in some parts of Asia, the rabies treatment market in APAC is projected to be the fastest-growing geographical segment in the global market. Technavio’s market research analysts anticipate the market for rabies treatment in the APAC region to account for a revenue of around USD 2,166 million by 2021.
According to Barath Palada, a lead analyst at Technavio, specializing in research on infectious and rare diseases, “Rabishield is the first fast-acting anti-rabies drug in the world and will be launched in India in 2016. It is a RMab and will cost 22%-24% lesser than existing HRIG. The launch of this drug is expected to address the low availability and affordability of monoclonal antibodies in the APAC market.”
Rabies treatment market in EMEA: The rise in awareness and the presence of well-established healthcare infrastructure in Europe are the fundamental driving forces behind growth of the rabies treatment market in EMEA. During the forecast period, advances in CCLs and veterinary vaccine preparation for rabies vaccine production technologies, coupled with continuous efforts by vendors to manufacture contamination-free vaccines with novel culture medias are expected to fuel further growth of the market.
Rabies treatment market in Americas: The rabies treatment market in the Americas is expected to grow at a lower rate during the forecast period due to the decreasing incidence of human rabies in this region, which decreases the demand for human rabies vaccine for post-exposure prophylaxis. The decline in the incidence of rabies is credited to the strict regulatory norms in the US, which mandates the annual vaccination of all domesticated animals such as dogs, cats, ferrets, and other livestock by their owners.
The leading vendors operating in the global rabies treatment market are:
- Cadila Healthcare
- GlaxoSmithKline
- Merial
- Sanofi
Other prominent vendors in the market include Merck and Pfizer.
A more detailed analysis is available in the Technavio report titled, ‘Global Rabies Treatment Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Orphan Drugs Market 2017-2021
- Global Bovine Respiratory Disease Treatment 2017-2021
- Global Animal Parasiticides Market 2017-2021
To read more press releases – click here
